A longitudinal study evaluating interim assessment of neoadjuvant chemotherapy for bladder cancer.
bladder cancer
computer tomography
imaging
neoadjuvant chemotherapy
patient management
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
22
07
2021
received:
29
04
2021
accepted:
07
08
2021
pubmed:
22
8
2021
medline:
26
8
2022
entrez:
21
8
2021
Statut:
ppublish
Résumé
To evaluate the usefulness of radiological re-staging after two and four cycles of neoadjuvant chemotherapy (NAC), the impact of re-staging on further patient management, and the correlation between clinical and final pathological tumour stage at radical cystectomy (RC). We conducted a longitudinal, single-centre, cohort study of prospectively collected consecutive patients who underwent NAC and RC for urothelial muscle-invasive bladder cancer between July 2001 and December 2017. Patients underwent repeated computed tomography scans for re-staging after two cycles of NAC and after completion of NAC before RC. Of 180 patients, 110 had ≥four cycles of NAC and had complete imaging available. In the entire cohort, further patient management was only changed in 2/180 patients (1.1%) after two cycles of NAC based on radiological findings. Patients who were stable after two cycles but then downstaged after at least four cycles of NAC had a similarly lowered risk of death (hazard ratio [HR] 0.53). Only one patient downstaged after two cycles was subsequently upstaged after four cycles. Clinical downstaging was observed in 51 patients (46%), 55 patients (50%) had no change in clinical stage and four patients (3.6%) were clinically upstaged. Patients clinically downstaged after four cycles of NAC had a lower risk of death (HR 0.49, 95% confidence interval 0.25-0.94; P = 0.033) compared to those with no change or upstaged after completion of NAC. Re-staging of muscle-invasive bladder cancer after two cycles of NAC offers little additional information, rarely changes patient management, and may therefore be omitted, whereas re-staging after completion of NAC by CT is a strong predictor of overall survival.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
306-313Informations de copyright
© 2021 The Authors BJU International © 2021 BJU International.
Références
Alfred Witjes J, Lebret T, Comperat EM et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2017; 71: 462-75
Advanced Bladder Cancer Meta-analysis C. Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data. Euro Urol 2005; 48: 202-6
Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349: 859-66
International Collaboration of T, Medical Research Council Advanced Bladder Cancer Working P, European Organisation for R, Treatment of Cancer Genito-Urinary Tract Cancer G, Australian Bladder Cancer Study G, National Cancer Institute of Canada Clinical Trials G et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011; 29: 2171-7
Zargar H, Espiritu PN, Fairey AS et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2015; 67: 241-9
Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Vavassori I, Barni S. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. Eur Urol 2014; 65: 350-7
Zargar H, Zargar-Shoshtari K, Lotan Y et al. Final pathological stage after neoadjuvant chemotherapy and radical cystectomy for bladder cancer-does pt0 predict better survival than pTa/Tis/T1? J Urol 2016; 195(Pt 1): 886-93
Kiss B, Thoeny HC, Studer UE. Current status of lymph node imaging in bladder and prostate cancer. Urology 2016; 96: 1-7
Shariat SF, Palapattu GS, Karakiewicz PI et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 2007; 51: 137-49
cancer EgM-iamb. 2020. [Available from: http://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/
Brierley JD ed. TNM classification of malignant tumors. UICC International Union Against Cancer, 8th edn. Chichester: Wiley; 2017
Regmi SK, Kalapara A, Konety BR. The need for interim assessment of neoadjuvant chemotherapy response for muscle invasive bladder cancer-can we help prevent definitive treatment delay in nonresponders? J Urol 2021; 205(2): 327-9
Reese AC, Ball MW, Gandhi N et al. The utility of an extensive postchemotherapy staging evaluation in patients receiving neoadjuvant chemotherapy for bladder cancer. Urology 2014; 84: 358-63
Advanced Bladder Cancer Meta-analysis C. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. The Lancet. 2003; 361: 1927-34
Ghadjar P, Burkhard FC, Gautschi O, Thalmann GN, Studer UE. Induction chemotherapy for unresectable urothelial carcinoma of the bladder. BJU Int 2010; 107: 894-7
Zargar-Shoshtari K, Zargar H, Lotan Y et al. A multi-institutional analysis of outcomes of patients with clinically node positive urothelial bladder cancer treated with induction chemotherapy and radical cystectomy. J Urol 2016; 195: 53-9
Peyton CC, Tang D, Reich RR et al. Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer. JAMA Oncol 2018; 4: 1535-42
Meyer A, Ghandour R, Bergman A et al. The natural history of clinically complete responders to neoadjuvant chemotherapy for urothelial carcinoma of the bladder. J Urol 2014; 192: 696-701
Paik ML, Scolieri MJ, Brown SL, Spirnak JP, Resnick MI. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol 2000; 163: 1693-6